March 26, 2020 / 8:22 PM / 12 days ago

BRIEF-Enanta Pharmaceuticals - Paused Recruitment And Dosing In Argon-2 Phase 2B Nash Study

Enanta Pharmaceuticals Inc:

* ENANTA PROVIDES UPDATE ON CLINICAL DEVELOPMENT ACTIVITIES DURING COVID-19 PANDEMIC

* ENANTA PHARMACEUTICALS - PAUSED RECRUITMENT AND DOSING IN ARGON-2 PHASE 2B NASH STUDY

* ENANTA PHARMACEUTICALS - PAUSING FURTHER RECRUITMENT IN PART 2 OF PHASE 1A/1B STUDY OF EDP-514 IN NUC-SUPPRESSED HEPATITIS B (HBV) PATIENTS

* ENANTA - CONTINUING TO PREPARE TO INITIATE 2 PHASE 2 RESPIRATORY SYNCYTIAL VIRUS STUDIES OF EDP-938 IN PEDIATRIC, TRANSPLANT PATIENTS LATER THIS YEAR

* ENANTA PHARMACEUTICALS - HAVE SUFFICIENT CASH RESOURCES TO BRIDGE US ACROSS CURRENT COVID-19 DISRUPTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below